Valproate Induced Non Hepatic Hyperammonaemic Encephalopathy (VNHE) - A study from Tertiary Care Referral University Hospital, North India

Journal of the Pakistan Medical Association

Volumn 58, Issue 11, 2008, Pages 627-631

  Mehndiratta, Man Mohan ^a   Mehndiratta, Prachi ^b   Phul, Puneet ^a   Garg, Siddhartha ^a  

^a G B PANT HOSPITAL   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ANTICONVULSIVE AGENT; CLOBAZAM; CLONAZEPAM; ETIRACETAM; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; AMMONIA BLOOD LEVEL; ARTICLE; BRAIN DISEASE; CHILD; CHOREA; CLINICAL ARTICLE; CONFUSION; DROWSINESS; DRUG BLOOD LEVEL; DYSTONIA; EPILEPSY; FEMALE; HUMAN; HYPERAMMONEMIA; INDIA; MALE; MONOTHERAPY; NON HEPATIC HYPERAMMONEMIC ENCEPHALOPATHY; SEIZURE; SENSORY DYSFUNCTION; TERTIARY HEALTH CARE; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; HYPERAMMONEMIA; INDIA; INFANT; MALE; NEUROTOXICITY SYNDROMES; VALPROIC ACID;

EID: 56049120341     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Perucca E.Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002; 16:695-714.
2. Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis. 2002; 17:367-73.
3. Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand. 2006; 114:1-7.
4. Gerstner T, Buesing D, Longin E, Bendl C, Wenzel D, Scheid B. et al. Valproic acid induced encephalopathy - 19 new cases in Germany from 1994 to 2003 - a side effect associated to VPA-therapy not only in young children. Seizure. 2006; 15:443-48.
5. Rath A, Naryanan TJ, Chowdhary GV, Murthy JM. Valproate-induced hyperammonemic encephalopathy with normal liver function. Neurol India. 2005; 53:226-28.
6. Mehndiratta MM. Valproate-Induced Non-Hepatic Hyperammonemic encephalopathy (VNHE): an important reversible encephalopathy. The NAD Science E-Journal 2005; 4:1-3.
7. Bhatia H, Raman PG. Valproate-induced hyperammonemic encephalopathy. J Assoc Physicians India. 2005; 53:158.
8. Panda S, Radhakrishnan K. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure. J Assoc Physicians India. 2004; 52:746-48.
9. Vossler DG, Wilensky AJ, Cawthon DF, Kraemer DL, Ojemann LM, Caylor LM. et al. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Epilepsia. 2002; 43:154-59.
10. Hug G, McGraw CA, Bates SR, Landrigan EA. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. J Pediatr. 1991; 119:799-802.
11. Iinuma K, Hayasaka K, Narisawa K, Tada K, Hori K. Hyperaminoacidaemia and hyperammonaemia in epileptic children treated with valproic acid. Eur J Pediatr. 1988; 148:267-69.
12. Murphy JV, Marquardt K. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol. 1982; 39:591-92.
13. Sackellares JC, Lee SI, Dreifuss FE. Stupor following administration of valproic acid to patients receiving other antiepileptic drugs. Epilepsia. 1979; 20:697-703.
14. Ziyeh S, Thiel T, Spreer J, Klisch J, Schumacher M. Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy. Epilepsia. 2002; 43:1101-05.
15. Ortiz-Sáenz de Santa María MR, Barriuso-Pérez E, Soto-Alvarez MI, Moche-Loeri JA. Ring chromosome 20, hypersensitivity to valproate and hyperammonemic encephalopathy. Rev Neurol. 2003 16-31; 37:733-35.
16. Bohan TP, Helton E, McDonald I, König S, Gazitt S, Sugimoto T. et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001; 56:1405-09.